OIG slaps PharMerica with $21.8 million kickback penalty

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.